A hallmark of smooth muscle cell (SMC) phenotypic switching is suppression of SMC maker gene expression. Although myocardin has been shown to be a key regulator of this process, the role of its related factors, MKL1 and MKL2, in SMC phenotypic switching remains unknown. The present studies were aimed at determining if: (1) MKL factors contribute to the expression of SMC marker genes in cultured SMCs; and (2) platelet-derived growth factor-BB (PDGF-BB)-induced repression of SMC marker genes is mediated by suppression of MKL factors.
Introduction
Differentiated smooth muscle cells (SMCs) in adult vessels exhibit a unique repertoire of gene expression such as smooth muscle (SM) -actin, SM-myosin heavy chain (SM-MHC), and SM22 , while expression of these SMC marker genes is decreased in response to vascular injury (28) . This plasticity of SMC phenotype is referred to as SMC phenotypic switching and plays a critical role in the development of atherosclerosis and restenosis after percutaneous coronary interventions (28) .
Platelet-derived growth factor-BB (PDGF-BB) is a key mediator of SMC phenotypic switching. It has been shown to potently suppress expression of SMC marker genes, as well as to increase the rate of proliferation and migration in cultured SMCs (4, 8, 20) . Expression of PDGF-BB and PDGF-receptor has been shown to be increased in the vascular lesions following mechanical injury and during atherosclerosis in vivo (8, 20) . Moreover, inhibition of PDGF-BB or PDGF-receptor signaling has been shown to attenuate neointimal thickening in several models of vascular injury and atherosclerosis (8, 20) . Given such a critical involvement of PDGF-BB in vascular lesion formation, elucidation of mechanisms whereby PDGF-BB represses SMC marker gene expression is likely to provide key insights towards understanding of the development of vascular disease.
Most SMC maker genes including SM -actin, SM-MHC, and SM22 contain multiple CArG [CC(AT-rich) 6 GG] elements in the promoter-enhancer regions, and expression of these genes is controlled by the ubiquitously expressed trans-binding factor, serum response factor (SRF), and its co-activator, myocardin (28) . Results of previous studies by our laboratory and others showed that myocardin was exclusively expressed in SMCs and cardiomyocytes, and markedly induced the transcription of multiple CArG-containing SMC marker genes in the presence of SRF (3, 6, 24, 29) , but failed to induce CArG-independent SMC marker genes such as smoothelin-B, acid carboxypeptidase-like protein (ACLP), and focal Page 3 of 36 4 adhesion kinase-related nonkinase (FRNK) (30) . Suppression of myocardin by either dominant-negative forms or short interfering RNA (siRNA) in cultured SMCs was associated with marked decreases in transcription of CArG-containing SMC marker genes (6, 29) .
Moreover, Li et al. (11) demonstrated that myocardin-deficient mice died by embryonic day 10.5 and showed no evidence of vascular SMC differentiation. However, myocardin does not appear to be necessarily required for the formation of SMCs, since recent studies using chimeric mice from the wild-type blastocysts injected with myocardin-null ES cells revealed that myocardin-null ES cells still gave rise to SMCs in vivo (18) . Of particular interest, PDGF-BB-induced suppression of SMC marker genes has been shown to be mediated, at least in part, through inhibition of formation of the CArG-SRF-myocardin complex (13, 26) . Wang et al. (26) showed that PDGF-BB induced phosphorylation of a ternary complex factor, Elk-1, and that phosphorylated Elk-1 inhibited the binding of myocardin to SRF, thereby reducing the transcription of CArG-dependent SMC marker genes in cultured A7r5 SMCs. We also showed that PDGF-BB repressed SMC marker gene expression through down-regulating myocardin expression and interfering with SRF binding to CArG elements in intact chromatin of cultured SMCs (13) . As such, the preceding results provide compelling evidence that regulation of formation of the CArG-SRF-myocardin complex plays a key role in the control of SMC marker gene expression.
MKL1 (also referred to as MAL, BSAC, MRTF-A) (2, 16, 21, 25) and MKL2 (also referred to as MRTF-B) (22, 25) have been identified as members of the family of myocardin-related transcription factors. Although both MKL factors have been shown to interact with SRF, MKL factors are widely expressed in many cell types in contrast to the SMC/cardiomyocyte-restricted expression pattern of myocardin (2, 7, 22, 25) . It has been shown that MKL1 and MKL2, respectively, induced the transcription of multiple CArG-containing SMC marker genes including Therefore, in the present studies, we investigated the involvement of MKL factors in PDGF-BB-induced suppression of SMC marker genes. We first determined the contribution of MKL factors to the expression of CArG-dependent and CArG-independent SMC marker genes using a combination of direct siRNA-induced gene suppression and over-expression studies, and then tested if PDGF-BB-induced repression of CArG-dependent SMC marker genes is mediated by the inhibition of MKL function in cultured SMCs.
Page 5 of 36

Materials and Methods
Plasmid Constructs and siRNA Duplexes
Rat SM -actin-luciferase (-2.6/+2.8 kb) construct and its triple CArG mutant were described previously (29 (GGAUGGCACUGUUAUUAGU) were purchased from MWG-BIOTECH Inc.
(High Point, NC).
Cell Culture, Transient Transfection, and PDGF-BB Stimulation
Rat aortic SMCs, A404 cells, 10T1/2 cells, and NIH/3T3 cells were cultured as described previously (29, 30) . Transfection of DNA plasmids was 
Reverse Transcription (RT)-PCR and Luciferase Assays
Total RNA was prepared from cultured cells after the induction of differentiation or after the transfection, and was used for semi-quantitative or real-time RT-PCR analyses. Primer and probe sequences for SM -actin, SM-MHC, SM22 , smoothelin-B, ACLP, myocardin, GAPDH, and 18S rRNA were described previously (30) . Primer and probe sequences for MKL1 and MKL2 were as follows:
Luciferase assays were performed as previously described (29) .
Western Blotting, Immunofluorescence, and Co-Immunoprecipitation Assays
Western blotting, immunofluorescence, and co-immunoprecipitation assays 
Chromatin Immunoprecipitation (ChIP) Assays
SMCs were fixed with 1% formaldehyde for 10 min at 37˚C to cross-link protein-DNA and protein-protein interactions within intact chromatin. Cells were harvested and the cross-linked chromatin was sonicated to shear chromatin fragments to 200-600 bps as described previously (9, 14) . Chromatin-protein complexes were immunoprecipitated with antibodies to MKL1, SRF, Elk-1, acetylated histone H4 (Upstate), HDAC2, HDAC4, or HDAC5 and salmon sperm DNA/protein A agarose. As a negative control, the antibody was excluded from the immunoprecipitation reaction. Samples were washed, reverse cross-linked, and purified. Recovered DNA was quantified by fluorescence with picogreen reagent (Molecular Probes, Eugene, OR). Real-time PCR was performed to amplify the CArG-containing region of the SM -actin and SM-MHC promoters. Primer sequences were previously described (14) . Data in ChIP assays are representative of 3 independent experiments.
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Results
MKL1 and MKL2 induced expression of single and multiple CArG-containing SMC marker genes, but not CArG-independent SMC marker genes
The initial aim of the present studies was to determine the expression and localization of MKL1 and MKL2 in our cultured SMCs derived from rat thoracic aorta. As shown in 
siRNA-induced suppression of MKL factors reduced CArG-dependent SMC marker gene expression in cultured SMCs
To test whether endogenous MKL1 and MKL2 contribute to the expression of SMC marker genes in SMCs, effects of siRNAs specific for MKL1 and MKL2
( Fig. 3A) on the transcription of SMC marker genes were examined in cultured SMCs. Suppression of MKL1 and MKL2 reduced the transcriptional activity of the SM -actin gene in SMCs by 75% and 42%, respectively, whereas suppression of myocardin reduced expression by 54% (Fig. 3B) . Likewise, suppression of MKL1 and MKL2 reduced the telokin promoter activity by 64% and 20%, respectively, Page 10 of 36 11 whereas suppression of myocardin reduced the transcription by 20%.
Myocardin-, MKL1-, and MKL2-specific siRNA duplexes were transfected into cultured SMCs, and expression of endogenous SMC marker genes measured by real-time RT-PCR (Fig. 3C) . Expression of myocardin, MKL1, and MKL2, respectively, was successfully reduced by the appropriate siRNA duplex.
Suppression of myocardin, MKL1, and MKL2 was associated with decreases in expression of endogenous SM -actin by 50%, 52%, and 55% and SM-MHC by 67%, 62%, and 68%, respectively. However, suppression of myocardin or MKL factors did not decrease smoothelin-B expression. In addition, there was no change in expression of the rest of myocardin/MKL factors to compensate for the lack of each factor. These results clearly indicate that each of the MKL factors contributes to the expression of CArG-dependent SMC marker genes in cultured SMCs.
PDGF-BB elicited the dissociation of MKL factors from CArG-containing SMC marker gene promoters in cultured SMCs
PDGF-BB has been shown to repress expression of CArG-dependent SMC marker genes including SM -actin and SM-MHC (4). We tested the hypothesis that suppression of SMC marker genes by PDGF-BB was in part mediated through the inhibition of MKL factors. First, the effect of PDGF-BB on expression of MKL factors was tested in cultured SMCs. Although PDGF-BB reduced mRNA expression of myocardin and CArG-dependent SMC marker genes, it did not decrease mRNA expression of MKL1 and MKL2 (Fig. 4A) . Treatment of SMCs with PDGF-BB also had no effect on MKL1 protein expression (Fig. 4B ). 
PDGF-BB-induced repression of SMC marker genes was mediated through the recruitment of HDAC2, HDAC4, and HDAC5 to the CArG-containing SMC marker gene promoters
Results of previous studies in our laboratory showed that treatment of SMCs with PDGF-BB for 24 hours induced hypoacetylation of histone H4 at the
CArG-containing region of SMC marker genes (14). Hypoacetylation of histone H4
has been demonstrated to restrict the accessibility of transcription factors to cognate DNA elements by forming the condensed chromatin structure, thereby suppressing gene transcription (15) . Although hypoacetylation is normally mediated by HDACs, it is unknown which HDACs mediate PDGF-BB-induced suppression of SMC marker gene expression. Thus, the following experiments were performed to examine the possible involvement of HDACs in this process. First, the effect of PDGF-BB on acetylation levels of histone H4 was examined by ChIP assays.
PDGF-BB caused a rapid and sustained reduction in acetyl histone H4 levels at the CArG-containing SMC marker gene promoters (Fig. 6A) . To determine which HDACs were capable of mediating this modification, expression plasmids for HDAC1 to HDAC7 were co-transfected into SMCs along with the SM -actin-luciferase construct. Results showed that HDAC2, HDAC4, and HDAC5 markedly reduced transcription of SMC marker genes (Fig. 6B) . However, the expression levels of these HDACs were not altered by the treatment with PDGF-BB (Fig. 6C) . Therefore, the association of these HDACs with the CArG-containing region of SMC marker genes was examined by ChIP assays (Fig. 6D) . Treatment of SMCs with PDGF-BB was associated with recruitment of HDAC2, HDAC4, and HDAC5 to the CArG-containing SMC marker gene promoters within 0.5 hours of PDGF-BB treatment, and the association of HDAC2 and HDAC5 was sustained through 24 hours. Effects of knockdown of these HDACs on PDGF-BB-mediated suppression of SMC marker genes were then tested. Results showed that PDGF-BB-induced suppression of SM -actin gene expression was markedly attenuated in SMCs transfected with siRNA duplexes specific for HDAC2 and HDAC5, while the effect of HDAC4 siRNA was somewhat less (i.e., a 89% reduction in control EGFP-treated SMCs as compared to 50%, 82%, and 60%
reductions, respectively, in SMCs treated with HDAC2, HDAC4, and HDAC5 siRNAs) (Fig. 7) . Taken together, results provide evidence that PDGF-BB recruits HDAC2, HDAC4, and HDAC5 to the CArG-containing regions of SMC marker genes, and that HDAC-induced hypoacetylation of histone H4 inhibits the accessibility of MKL factors to the CArG-containing regions within intact chromatin, and thereby reduces transcription of SMC marker genes.
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Discussion
Although MKL2 has been shown to be required for SM -actin expression in neural crest-derived SMCs during the early embryonic development (10, 17) , its role in adult SMCs or local mesoderm-derived SMCs is unknown. Likewise, although Du et al. (7) showed that a truncated mutant of MKL1 repressed MKL1-induced activation of the SM22 gene in a dominant-negative manner, the effect of MKL1 on SMC marker gene expression is still unclear because the dominant-negative MKL1 used in these studies also inhibited effects of myocardin.
Results Previous studies showed that PDGF-BB-induced suppression of SMC marker genes was mediated in part through displacement of myocardin from SRF triggered by phosphorylated Elk-1, down-regulation of myocardin expression, and reduced SRF binding to CArG elements of SMC marker gene promoters (13, 26) .
The present studies extend these results by testing if multiple repressor mechanisms contribute to PDGF-BB-induced suppression of SMC marker genes and if these vary at multiple time points after PDGF-BB exposure. Our observations can be summarized as follows (Fig. 8) . First, we found that the mechanism whereby phosphorylated Elk-1 displaced myocardin from SRF was applicable to MKL factors, but this mechanism was only present at very early time points. Second, we
showed that, although expression of myocardin was decreased, expression of MKL factors was unaltered by PDGF-BB treatment. Third, we showed that the association of MKL factors with CArG-containing SMC marker gene promoters Results of the present studies also showed that HDAC2, HDAC4, and HDAC5 were involved in the repression of SMC marker genes by PDGF-BB.
Indeed, ChIP assays revealed the recruitment of these HDACs to the CArG-containing SMC marker gene promoters by treatment with PDGF-BB in cultured SMCs. Moreover, we showed that siRNA-induced knockdown of these HDACs attenuated PDGF-BB-mediated repression of SM -actin gene expression.
Although the present studies were the first to identify which HDACs were employed to repress SMC marker genes by PDGF-BB, results of several previous studies support our results. First, Qiu and Li (19) showed that treatment of 10T1/2 embryonic fibroblasts with trichostatin A, an HDAC inhibitor, increased the activity of the SM22 gene, whereas it did not increase the activity of this CArG-mutation 
